Patents by Inventor Verena Lutz

Verena Lutz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Predictive marker for EGFR inhibitor treatment
    Patent number: 9121067
    Abstract: The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.
    Type: Grant
    Filed: April 1, 2013
    Date of Patent: September 1, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110312981
    Abstract: The present invention provides a biomarker SFRS7 which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.
    Type: Application
    Filed: August 7, 2008
    Publication date: December 22, 2011
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110245279
    Abstract: The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients
    Type: Application
    Filed: August 7, 2008
    Publication date: October 6, 2011
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110230506
    Abstract: The present invention provides a biomarker (RAPGEF5) that is predictive for the response to treatment with an EGFR inhibitor in cancer patients.
    Type: Application
    Filed: August 7, 2008
    Publication date: September 22, 2011
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110212979
    Abstract: The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.
    Type: Application
    Filed: August 7, 2008
    Publication date: September 1, 2011
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110195982
    Abstract: The present invention provides a biomarker that is predictive for the response to treatment with an EGFR inhibitor in cancer patients
    Type: Application
    Filed: August 7, 2008
    Publication date: August 11, 2011
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110190321
    Abstract: The present invention provides a biomarker that is predictive for the response to treatment with an EGFR inhibitor in cancer patients.
    Type: Application
    Filed: August 7, 2008
    Publication date: August 4, 2011
    Inventors: Paul Delmar, Barbara Kiughammer, Verena Lutz, Patricia McLoughlin
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110184005
    Abstract: The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.
    Type: Application
    Filed: August 7, 2008
    Publication date: July 28, 2011
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110184004
    Abstract: The present invention provides biomarkers which are predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.
    Type: Application
    Filed: August 7, 2008
    Publication date: July 28, 2011
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin
  • DETERMINATION OF RESPONDERS TO CHEMOTHERAPY
    Publication number: 20100196931
    Abstract: The present invention relates to a method of determining whether a biological sample comprising human lung cancer cells is sensitive to a combination of an epidermal growth factor receptor inhibitor and a chemotherapeutic agent by determining the overexpression of a phosphorylated AKT protein and/or a phosphorylated MAPK protein in the biological sample. The invention is also related to methods for deriving a candidate agent or for selecting a composition for inhibiting the progression of lung cancer in a patient wherein a phosphorylated AKT protein and/or a phosphorylated MAPK protein is used.
    Type: Application
    Filed: November 19, 2009
    Publication date: August 5, 2010
    Inventors: Ulrich Brennscheidt, Otmar Herrgott, Astrid Heller, Verena Lutz, Joachim Moecks, Carol Ward
  • Determination of responders to chemotherapy
    Patent number: 7655414
    Abstract: The present invention relates to a method of determining whether a biological sample comprising human lung cancer cells is sensitive to a combination of an epidermal growth factor receptor inhibitor and a chemotherapeutic agent by determining the overexpression of a phosphorylated AKT protein and/or a phosphorylated MAPK protein in the biological sample. The invention is also related to methods for deriving a candidate agent or for selecting a composition for inhibiting the progression of lung cancer in a patient wherein a phosphorylated AKT protein and/or a phosphorylated MAPK protein is used.
    Type: Grant
    Filed: May 10, 2006
    Date of Patent: February 2, 2010
    Assignee: Hoffman La-Roche Inc.
    Inventors: Ulrich Brennscheidt, Otmar Herrgott, legal representative, Astrid Heller, Verena Lutz, Joachim Moecks, Carol Ward
  • Urokinase inhibitors and uses thereof
    Patent number: 7342018
    Abstract: The invention relates to the use of derivatives of 3-amidinophenylalanine as urokinase inhibitors for treating malignant tumors and the formation of metastases.
    Type: Grant
    Filed: October 24, 2003
    Date of Patent: March 11, 2008
    Assignee: Wilex AG
    Inventors: Olaf Wilhelm, Viktor Magdolen, Jörg Stürzebecker, John Foekens, Verena Lutz
  • Determination of responders to chemotherapy
    Publication number: 20070054330
    Abstract: The present invention relates to a method of determining whether a biological sample comprising human lung cancer cells is sensitive to a combination of an epidermal growth factor receptor inhibitor and a chemotherapeutic agent by determining the overexpression of a phosphorylated AKT protein and/or a phosphorylated MAPK protein in the biological sample. The invention is also related to methods for deriving a candidate agent or for selecting a composition for inhibiting the progression of lung cancer in a patient wherein a phosphorylated AKT protein and/or a phosphorylated MAPK protein is used.
    Type: Application
    Filed: May 10, 2006
    Publication date: March 8, 2007
    Inventors: Ulrich Brennscheidt, Otmar Herrgott, Astrid Heller, Verena Lutz, Joachim Moecks, Carol Ward
  • Methods and compositions related to prediction of drug response
    Publication number: 20050100936
    Abstract: The present invention is directed to a method for determining whether a patient suffering from cancer will be responsive to a treatment with a 5-Fluoro-Uracil and/or 5-Fluoro-Uracil analogs. Specifically, the invention relates to methods of determining the expression levels of certain mRNAs to determine responsiveness to drug treatment.
    Type: Application
    Filed: August 26, 2004
    Publication date: May 12, 2005
    Applicant: ROCHE MOLECULAR SYSTEMS, INC.
    Inventors: Verena Lutz, Friedemann Krause, Manuela Poignee, Thomas Walter, Baerbel Porstmann, Martin Werner, Silke Lassmann
  • Novel urokinase inhibitors
    Publication number: 20040138233
    Abstract: The invention relates to the use of derivatives of 3-amidinophenylalanine as urokinase inhibitors for treating malignant tumors and the formation of metastases.
    Type: Application
    Filed: October 24, 2003
    Publication date: July 15, 2004
    Applicant: WILEX AG
    Inventors: Olaf Wilhelm, Viktor Magdolen, Jorg Sturzebecker, John Foekens, Verena Lutz
  • Urokinase inhibitors
    Patent number: 6680320
    Abstract: The invention relates to the use of derivatives of 3-amidinophenylalanine as urokinase inhibitors for treating malignant tumors and the formation of metastases.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: January 20, 2004
    Assignee: Wilex AG
    Inventors: Olaf Wilhelm, Viktor Magdolen, Jörg Stürzebecher, John Foekens, Verena Lutz
  • Urokinase inhibitors
    Patent number: 6624169
    Abstract: The invention relates to the use of derivatives of 3-amidinophenylalanine as urokinase inhibitors for treating malignant tumors and the formation of metastases.
    Type: Grant
    Filed: April 3, 2001
    Date of Patent: September 23, 2003
    Assignee: Wilex Biotechnology GmbH
    Inventors: Olaf Wilhelm, Viktor Magdolen, Jörg Stürzebecher, John Foekens, Verena Lutz
  • Novel urokinase inhibitors
    Publication number: 20030013723
    Abstract: The invention relates to the use of derivatives of 3-amidinophenylalanine as urokinase inhibitors for treating malignant tumors and the formation of metastases.
    Type: Application
    Filed: July 26, 2002
    Publication date: January 16, 2003
    Applicant: Wilex AG
    Inventors: Olaf Wilhelm, Viktor Magdolen, Jorg Sturzebecher, John Foekens, Verena Lutz